

CSD/BSE&NSE/2024-25

23 July 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Sub: Receipt of Observation Letter with “no adverse observations” from BSE Limited and “no objection” from the National Stock Exchange of India Limited for the scheme of amalgamation that seeks amalgamation of Cohance Lifesciences Limited (“Transferor Company”) into and with Suven Pharmaceuticals Limited (“Transferee Company”) under Sections 230 to 232 of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder (“Scheme of Amalgamation”).

Ref: Application for obtaining approval under Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) with respect to the scheme of amalgamation.

Dear Sir/Madam,

This is with reference to and in furtherance of our letter dated 29 February 2024 pursuant to which we informed about the decision of the Board of Directors of Suven Pharmaceuticals Limited approving the Scheme of Amalgamation, subject to receipt of applicable regulatory and other approvals.

In this regard, we would like to inform you that the Company has received today (i.e., 23 July 2024) observation letter with “no adverse observations” dated 19 July 2024 from BSE Limited and observation letter with “no objection” dated 23 July 2024 from the National Stock Exchange of India Limited respectively in relation to the Scheme of Amalgamation.

The Scheme of Amalgamation remains subject to applicable approvals, including approvals from the respective jurisdictional Hon’ble National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities, as may be applicable.

This is for your information and record.

Thanking you.

Yours faithfully,

For Suven Pharmaceuticals Limited

K. Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIIIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236